A5047331276- Pulmonary Hypertension Research and Treatments
- Cardiovascular Issues in Pregnancy
- Cardiovascular Function and Risk Factors
- Liver Disease and Transplantation
- Vascular Anomalies and Treatments
- Congenital Heart Disease Studies
- Venous Thromboembolism Diagnosis and Management
- Hepatitis C virus research
- Cardiac tumors and thrombi
- Heart Failure Treatment and Management
- Liver Disease Diagnosis and Treatment
- Cardiomyopathy and Myosin Studies
- Transplantation: Methods and Outcomes
- Cardiac Valve Diseases and Treatments
- Medical Imaging and Pathology Studies
- Cardiac, Anesthesia and Surgical Outcomes
- Cancer, Stress, Anesthesia, and Immune Response
- Vascular Malformations and Hemangiomas
- Phosphodiesterase function and regulation
- Tracheal and airway disorders
- Pericarditis and Cardiac Tamponade
- Cardiac Imaging and Diagnostics
- Infrared Thermography in Medicine
- Anesthesia and Pain Management
- Lung Cancer Diagnosis and Treatment
University of Bologna
2017-2024
Policlinico S.Orsola-Malpighi
2019-2024
Azienda USL di Bologna
2023
Istituti di Ricovero e Cura a Carattere Scientifico
2023
Okayama Medical Center
2022
National Hospital Organization
2022
Background Haemodynamic variables like right atrial pressure (RAP), cardiac index (CI), stroke volume (SVI) and mixed venous oxygen saturation ( S vO 2 ) predict survival in patients with pulmonary arterial hypertension (PAH). However, there is the need to identify further prognostic haemodynamic parameters as well redefine their role PAH risk stratification compared current tools non-invasive parameters. Methods This cohort study includes treatment-naïve assessed at baseline after...
To optimise treatment of patients with pulmonary arterial hypertension (PAH), the 2015 European Society Cardiology/European Respiratory guidelines recommend using risk stratification, aim achieving low-risk status. Previous analyses registries made progress in stratification approaches, however, focus is often on a prognosis, whereas most PAH are intermediate-risk or high-risk categories. Using only six parameters high prognostic relevance, we aimed to demonstrate pragmatic approach...
Abstract Background Hemodynamic variables such as right atrial pressure, cardiac index (CI), stroke volume (SVI), and mixed venous oxygen saturation have consistently been associated with survival in pulmonary arterial hypertension (PAH). New PAH treatments are, however, able to improve short–term outcome reducing mean pressure (mPAP) vascular resistance (PVR) without increasing CI or SVI. The prognostic role of a mPAP <35 mmHg at follow–up PVR values <5 WU prevalent patients...
Abstract Background Hemodynamic variables related to right ventricular (RV) function have consistently been associated with survival in pulmonary arterial hypertension (PAH). New PAH treatments, however, seems improve RV coupling reducing afterload [e.g. mean pressure (mPAP) and vascular resistance (PVR)], but without increasing cardiac output. The prognostic role of a mPAP <35 mmHg at follow–up PVR values <5 WU prevalent patients described. Objective aim this work was define...
Abstract Background Hemodynamic variables such as right atrial pressure (RAP), cardiac index (CI) and mixed venous oxygen saturation (SvO2) have consistently been associated with survival in pulmonary arterial hypertension (PAH). The prognostic importance of hemodynamics after treatment initiation seems to be superior baseline evaluation stroke volume (SVI) emerged an independent parameter. New PAH treatments are, however, able improve exercise capacity without increasing CI or SVI. Purpose...
Abstract Rationale Pulmonary endarterectomy (PEA) has been the most effective therapy for chronic thromboembolic pulmonary hypertension (CTEPH). However, there is a substantial proportion of patients declared not operable in whom other treatment strategies are available: medical and balloon angioplasty (BPA). We aimed to compare different CTEPH effect real-world setting. Methods All referred our Centre were included. short-term clinical, functional, exercise haemodynamic (irrespective...
Abstract Background Pulmonary arterial hypertension (PAH) is a rare complication of both HIV infection (HIV-PAH) and portal (Po-PAH); it can occur in patients with diseases (HIV/Po-PAH). The use the PAH-specific drug classes (prostanoids, endothelin-1 receptor antagonists [ERA] phosphodiesterase-5 inhibitors [PDE5-i]) largely justified by retrospective observational case reports since, to date, there are no randomized clinical trials except for PORTICO trial which demonstrated efficacy...
Abstract The combination of an initial clinical approach aimed at evaluating the early risk mortality with subsequent diagnostic and therapeutic approaches articulated on overall patient’s profile is recommended in acute pulmonary embolism (PE). presence hypertension associated persistence chronic vascular obstructions arteries after one or more thrombo-embolic events identifies a condition defined as (CTEPH). evolution technology knowledge field imaging has allowed us to qualify computed...
Pulmonary arterial hypertension (PAH) may complicate both portal (Po-PAH) and HIV infection (HIV-PAH). These two conditions, however, frequently coexist in the same patient (HIV/Po-PAH). We evaluated clinical, functional, hemodynamic characteristics prognostic parameters of these three groups patients. included patients with Po-PAH, HIV-PAH HIV/Po-PAH referred to a single center. compared functional parameters, severity liver disease [Child-Turcotte-Pugh (CTP) Model for End-stage Liver...
Balloon pulmonary angioplasty (BPA) represents a therapeutic option for the treatment of chronic thromboembolic hypertension (CTEPH) in patients who are not eligible surgical endarterectomy (PEA) or with persistent/recurrent symptomatic arterial after PEA. This study evaluated safety BPA during 5 years experience only Italian center systematically performing this procedure.The program was activated at S. Orsola Polyclinic Bologna June 2015. Life-threatening periprocedural complications were...
Abstract Background Current pulmonary hypertension (PH) guidelines stratify the risk of patients with arterial (PAH) using a multiparametric approach. Low, intermediate and high-risk are defined by estimated 1-year mortality <5%, 5–10% >10%, respectively. This assessment has been recently validated in 3 cohorts PAH simplified table for idiopathic/heritable (I/H) associated connective tissue disease (CTD) congenital heart (CHD) proposed validated. However, this method most classified...
Abstract Background Balloon pulmonary angioplasty (BPA) has recently been developed as an alternative and less-invasive treatment strategy for chronic thromboembolic hypertension (CTEPH) but therapeutic efficacy technical safety of the technique have to be established. Purpose To examine effects BPA on patients with inoperable disease or residual (PH) after endarterectomy (PEA). Methods From June 2015 January 2019 we enrolled symptomatic (WHO-FC ≥II) CTEPH PH PEA. At baseline 3 months last...